Selección de publicaciones

  • Cortazar AR, Torrano V, Martín-Martín N, Caro-Maldonado A, Camacho L, Hermanova I, Guruceaga E, Lorenzo-Martín LF, Caloto R, Gomis RR, Apaolaza I, Quesada V, Trka J, Gomez-Muñoz A, Vicent S, Bustelo XR, Planes FJ, Aransay AM, Carracedo A. CANCERTOOL: a visualization and representation interface to exploit cancer datasets. Cancer Res. 2018 Sep 19. pii: canres.1669.2018. doi: 10.1158/0008-5472.CAN-18-1669.

  • Rodriguez J, Vicent S, Chopitea A, Ponz-Sarvisé M. Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center. Clin Cancer Res. 2018 Aug 15;24(16):3787-3789.

  • Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S*, Gil-Bazo I* (equal senior contribution). KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018 Feb 19;17(1):33.

  • Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F. Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176.

  • Vallejo A, Valencia K, Vicent S. All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. Mol Cell Oncol. 2017 Apr 5;4(3):e1314239.

  • Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discov. 2017 Jul;7(7):694-703.

  • Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun. 2017 Feb 21;8:14294.

  • Gil-Bazo I, Sweet-Cordero A, Vicent S. The present and the future of the RAS pathway: From function and genomics to inhibition. Cancer Biol Ther. 2016 Jul 2;17(7):719-22.

  • Urtasun R, Elizalde M, Azkona M, Latasa MU, García-Irigoyen O, Uriarte I, Fernández-Barrena MG, Vicent S, Alonso MM, Muntané J, Prieto J, Ávila MA, Berasain C. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. Oncogene. 2016 Sep 8;35(36):4719-29.

  • Chen R, Khatri P, Mazur PK, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 2014 May 15;74(10):2892-902.

  • Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, Shrager J, Hoang CD, Plevritis S, Butte AJ, Sweet-Cordero EA. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012 Nov 15;72(22):5744-56. 

  • Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010 Nov;120(11):3940-52.


"Estamos muy interesados en identificar nuevas dianas moleculares en tumores dependientes de KRAS y en descubrir estrategias terapéuticas innovadoras para el tratamiento de estos tumores", Dr. Silve Vicent.

Contactar

Contacto:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 1010
msripa@unav.es